Evidence for solanidine as a dietary CYP2D6 biomarker: Significant correlation with risperidone metabolism.
Birgit M WollmannRobert Løvsletten SmithMarianne Kristiansen KringenMagnus Ingelman-SundbergEspen MoldenElisabet StørsetPublished in: British journal of clinical pharmacology (2023)
The present study shows strong, positive correlations between solanidine metabolism and CYP2D6-mediated risperidone metabolism. The strong correlation within patients carrying CYP2D6 genotypes encoding functional CYP2D6 metabolism suggests that solanidine metabolism may predict individual CYP2D6 metabolism, and hence potentially improve personalized dosing of drugs metabolized by CYP2D6.